url:https://finance.yahoo.com/m/b1e2f410-9fe9-3981-8093-3da68449048d/one-month-ahead-of-its-most.html
title:One_Month_Ahead_of_its_Most_Crucial_Moment_Ever_Should_You_Buy_CRISPR_Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) has reached a very important chapter in its growth story. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel, the company's gene-editing candidate for sickle cell disease, next month. Does all of this mean now is the time to buy CRISPR Therapeutics?